MedTrace Logo

Role of Mosapride in Patients With Gastroesophageal Reflux Disease

NCT00729339 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2009-05-13

No results posted yet for this study

Summary

Gastroesophageal reflux disease (GERD) is a very common disease in the Western World. In Taiwan, this disease is increasing gradually because the investigators' eating style is closing to Western world.

Proton pump is the main drug for patients with GERD in the past two decades. Prokinetic agent is an important adjuvant to the therapy of GERD. This study aims to evaluate the role of prokinetic agent in the management of GERD.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

mosapride for the first month and placebo for the 2nd month

lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month

DRUG

placebo for the first and mosapride for the second month

lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month

Sponsors & Collaborators

  • Tomorrow Medical Foundation

    collaborator OTHER

  • Lotung Poh-Ai Hospital

    lead OTHER

Principal Investigators

  • Hwai-Jeng Lin, M.D. · Lotung Poh-Ai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-04-30
Completion
2009-05-31

Countries

  • Taiwan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00729339 on ClinicalTrials.gov